繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Hain Celestial预计2014年利润率有所改善

2024-08-27 19:25

Hain Celestial Group (NASDAQ:HAIN) posted mixed numbers with its FQ4 earnings report.

Revenue fell 6% year-over-year to $418.8 million for the quarter that ended on June 30. Sales in North America were down 8%, while sales fell 4% for the International segment. Total organic sales decreased 4% during the quarter. A 5% decline in organic sales in North Americas was due primarily to lower sales in personal care, in part due to portfolio simplification, as well as reduced sales in infant formula within baby and kids, partially offset by growth in snacks. The 4% drop in international organic sales was due primarily to lower sales in plant-based meat free within meal prep as well as in snacks, partially offset by growth in beverages.

The strongest category for Hain Celestial (HAIN) during FQ4 was beverages (+5% growth), while the personal care (-21%) and baby & kids (-10%) categories lagged.

Adjusted gross profit margin improved 70 basis points to 23.4% of sales vs. 23.0% consensus. Adjusted EBITDA was $40 million, compared to $44 million a year ago. The company's adjusted earnings per share mark was reported at $0.13 vs. $0.08 consensus and $0.11 a year ago.

On the balance sheet, Hain Celestial's (HAIN) net cash provided by operating activities in FQ4 was $39 million, compared to $41 million in the prior year period. Free cash flow was $31 million, compared to $34 million in the prior year period. Total debt at the end of the fiscal year was $744 million, down from $829 million at the beginning of the fiscal year. Net debt at the end of the fiscal year was $690 million, compared to $775 million at the beginning of the fiscal year.

Looking ahead, Hain Celestial (HAIN) expects organic net sales growth to be flat or better. Adjusted EBITDA is expected to grow by mid-single-digits.

Shares of Hain Celestial (HAIN) rose 2.35% in premarket trading to $6.99 vs. the 52-week range of $5.69 to $12.49.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。